ReviewJournal of perinatology : official journal of the California Perinatal Association2026
Adverse maternal and neonatal effects associated with perinatal xylazine exposure: a systematic review.
Review in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perinatal opioid exposure is increasingly studied, though our understanding of xylazine, a veterinary sedative-turned-fentanyl adulterant, is less robust. The majority of published xylazine data is animal-derived, despite broader drug testing that identifies increased incidental human exposure and prolonged sedation. Xylazine's clinical sequelae are often underrecognized, especially in pregnant populations. We systematically reviewed five databases for literature on xylazine exposure in human pregnancy. We identified eleven discrete reports, where seven described clinical outcomes, and four measured toxicology data indicating xylazine exposure. In both categories, most studies focused on fetal outcomes and umbilical cord tissue testing, which highlighted xylazine transmission to the fetus. Only three studies reported any data on maternal outcomes. Findings suggest that not only is human-derived data on xylazine exposure limited, but maternal outcomes are particularly understudied despite evidence of prevalent exposure.
Identifiers
42192162What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.